BIOPHARM FORWARD ApS: Financial statements 2022
CVR: 32438784
Source: annual report 2022, Danish Business Authority
26/08/2021 – 25/08/2022
BIOPHARM FORWARD ApS (CVR 32438784) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 584,101 and a net result of DKK 156,128 compared with DKK 1,456,847 the year before. That is a decrease of 37.1% compared with the year before. Equity in the 2022 report amounted to DKK 1,594,695. The solvency ratio was 87.2%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 584,101
- Profit/Loss
- DKK 156,128
- Equity
- DKK 1,594,695
- Total Assets
- DKK 1,828,733
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 584 t. | 156 t. | 1.6 mio. | 1 |
| 2021 | - | 928 t. | 1.5 mio. | 1.6 mio. | 1 |
| 2020 | - | 182 t. | 146 t. | 209 t. | 1 |
| 2019 | - | 291 t. | 201 t. | 171 t. | 0 |
| 2018 | - | -2 t. | -2 t. | -30 t. | - |
Official annual report
Keep an eye on BIOPHARM FORWARD ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
BIOPHARM FORWARD ApS has published its annual report for 2021. Gross profit came to DKK 928,008, and the net result was DKK 1,456,847.
About BIOPHARM FORWARD ApS
BIOPHARM FORWARD ApS is a Danish company of the type Anpartsselskab based in Espergærde, founded in 2009. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jonas Hink. The company is owned by Jonas Hink. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 997,234 and a net result of DKK 243,660 compared with DKK 385,061 the year before. Equity in the 2025 report amounted to DKK 1,741,315.